ArticleClinical epidemiology2013
Comorbidity and survival of Danish ovarian cancer patients from 2000-2011: a population-based cohort study.
Article in Clinical epidemiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Survival rate of ovarian cancer in Asian countries: a systematic review and meta-analysis.BMC cancer · 2023Pooled it
- Comorbidity and survival among women with ovarian cancer: evidence from prospective studies.Scientific reports · 2015Pooled it
- Evaluating Comorbidity Scores in Geriatric Ovarian Cancer: A Retrospective Cohort Analysis.Medicina (Kaunas, Lithuania) · 2026Article
- Association of medical comorbidities and cardiovascular disease with toxicity and survival among patients receiving checkpoint inhibitor immunotherapy.Cancer immunology, immunotherapy : CII · 2023Article
- Development of a nomogram for predicting survival of patients with ovarian serous cystadenocarcinoma after based on SEER database.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2021Article
- Analysis of Morbidity, Mortality and Survival Pattern Following Surgery for Borderline Ovarian and Malignant Ovarian Tumour in Tertiary Care Centre.Journal of obstetrics and gynaecology of India · 2021Article
- Complications and Survivorship Trends After Primary Debulking Surgery for Ovarian Cancer.The Journal of surgical research · 2020Article
- Impact of Age, Comorbidity, and FIGO Stage on Treatment Choice and Mortality in Older Danish Patients with Gynecological Cancer: A Retrospective Register-Based Cohort Study.Drugs - real world outcomes · 2018Article
- Article
- Predictors of mortality within 1 year after primary ovarian cancer surgery: a nationwide cohort study.BMJ open · 2016Article
- The Clinicopathologic Characteristics and 5-year Survival Rate of Epithelial Ovarian Cancer in Yazd, Iran.Electronic physician · 2015Article
- Association of comorbidities with postoperative in-hospital mortality: a retrospective cohort study.Medicine · 2015Observational
- Weight change therapy as a potential treatment for end-stage ovarian carcinoma.The American journal of case reports · 2014Article
- Age-adjusted charlson comorbidity index and 30-day morbidity in pelvic surgeries.South Asian journal of cancerArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo examine the prevalence of comorbidity among patients diagnosed with epithelial ovarian cancer in the Central Denmark Region and to study the impact of comorbidity on cancer survival over time.
methodsWe included women recorded with a first-time diagnosis of epithelial ovarian cancer in the Danish National Registry of Patients in the Central Denmark region between 2000 and 2011. We followed their survival through the Danish Civil Registration System. We estimated 1- and 5-year survival overall and stratified by Charlson Comorbidity Index score. We used Cox proportional hazard regression analyses to compute adjusted mortality rate ratios (MRRs) within different calendar time periods overall and by comorbidity level.
resultsWe identified 1,540 patients. In 2000-2002, 25% of the newly diagnosed ovarian cancer patients had a comorbidity diagnosis compared with 35% in 2009-2011. Median age increased from 61 to 66 years. One-year overall survival changed from 73% (95% confidence interval [CI]: 69-78) in 2000-2002 to 69% (95% CI: 63-73) in 2009-2011, corresponding to an age- and comorbidity-adjusted MRR of 1.03 (95% CI: 0.79-1.36). Five-year survival changed only slightly during the study period, from 37% (95% CI: 32-42) in 2000-2002 to 39% (95% CI: 34-44) in 2009-2011. In patients with Charlson score ≥3, 1-year survival changed from 63% (95% CI: 35-81) in 2000-2002 to 41% (95% CI: 24-57) in 2003-2005 and thereafter stabilized. One-year survival changed from 56% (95% CI: 44-66) to 64% (95% CI: 53-74) in patients with Charlson score 1-2. Compared with Charlson score 0, adjusted 1-year MRRs for Charlson score ≥3 were 1.44 (95% CI: 0.62-3.36) in 2000-2002 and 2.11 (95% CI: 1.27-3.51) in 2009-2011, whereas adjusted 1-year MRRs for Charlson score 1-2 changed from 2.04 (95% CI: 1.33-3.14) in 2000-2002 to 1.09 (95% CI: 0.69-1.71) in 2009-2011.
conclusionComorbidity increased among ovarian cancer patients over time and was associated with poor survival. One- and 5-year overall survivals changed only little and an expected decrease in survival, following increased prevalence of comorbidity and increasing age of patients, may have been counteracted by more aggressive surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.